Dude, be realistic. TGA, FDA, EMA etc all publish guidance on their process times. PR talked it up big time. They all do. Its common place in Aussie bio-techs. He blatantly back tracked on guidance, then tried to backtrack on amended guidance on occassion. The company, like most, was effected by COVID, but that doesn't cover much of the optimism (embellishments) on guidance given.
The stock is good value down here, but many medium-term share holders bought the kool-aid at $3-4 and I feel sorry for them.
PAR General discussion, page-95
-
- There are more pages in this discussion • 245 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
-0.010(4.17%) |
Mkt cap ! $83.98M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 22.5¢ | $167.1K | 714.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 120730 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 49999 | 1 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |